Travere Therapeutics, Inc.
TVTX
$28.18
$0.381.37%
NASDAQ
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -21.33% | 44.05% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -21.33% | 44.05% | |||
| Cost of Revenue | 12.99% | 5.09% | |||
| Gross Profit | -37.81% | 75.23% | |||
| SG&A Expenses | 17.63% | 13.43% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 15.86% | 10.09% | |||
| Operating Income | -230.07% | 297.08% | |||
| Income Before Tax | -181.92% | 301.92% | |||
| Income Tax Expenses | 11,412.50% | -60.00% | |||
| Earnings from Continuing Operations | -185.53% | 301.54% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | -89.38% | 301.54% | |||
| EBIT | -230.07% | 297.08% | |||
| EBITDA | -135.10% | 2,880.89% | |||
| EPS Basic | -89.52% | 300.91% | |||
| Normalized Basic EPS | -180.96% | 301.23% | |||
| EPS Diluted | -89.03% | 292.05% | |||
| Normalized Diluted EPS | -193.10% | 274.97% | |||
| Average Basic Shares Outstanding | 1.19% | 0.32% | |||
| Average Diluted Shares Outstanding | -12.01% | 15.37% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||